Alaska Permanent Fund Corp Has $1.91 Million Holdings in Organon & Co. (NYSE:OGN)

Alaska Permanent Fund Corp grew its position in Organon & Co. (NYSE:OGN) by 12.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 132,078 shares of the company’s stock after buying an additional 14,478 shares during the quarter. Alaska Permanent Fund Corp owned approximately 0.05% of Organon & Co. worth $1,905,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Harvest Fund Management Co. Ltd boosted its stake in Organon & Co. by 495.5% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Lindbrook Capital LLC boosted its position in shares of Organon & Co. by 348.3% in the fourth quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after buying an additional 1,428 shares during the period. Headlands Technologies LLC purchased a new position in shares of Organon & Co. during the third quarter valued at $35,000. EverSource Wealth Advisors LLC raised its position in Organon & Co. by 97.7% during the third quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock valued at $39,000 after buying an additional 1,110 shares during the period. Finally, Clear Street Markets LLC lifted its stake in Organon & Co. by 588.9% in the 3rd quarter. Clear Street Markets LLC now owns 2,294 shares of the company’s stock worth $40,000 after acquiring an additional 1,961 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group boosted their price objective on shares of Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, February 20th.

Organon & Co. Price Performance

OGN opened at $18.50 on Friday. The company has a market capitalization of $4.73 billion, a PE ratio of 4.61, a price-to-earnings-growth ratio of 0.89 and a beta of 0.83. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The business has a 50-day moving average of $18.14 and a 200-day moving average of $15.69.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. On average, equities research analysts expect that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 6.05%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s dividend payout ratio is presently 28.00%.

Insider Buying and Selling

In related news, insider Kirke Weaver purchased 2,720 shares of Organon & Co. stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the transaction, the insider now directly owns 15,181 shares of the company’s stock, valued at $278,723.16. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.17% of the stock is currently owned by corporate insiders.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.